reason report
analyst meet highlight long-term contribut on-going
bottom line yesterday attend bax biannual investor meet
nyc share outperform yesterday reaction posit
analyst meet manag guid sale growth compound-annual-growth-rate
top-lin growth acceler
compound-annual-growth-rate compound-annual-growth-rate
adjust oper margin expans guid
ramp top
expect continu gener strong free cash flow
next year target
expect surfac long-term
guidanc updat seem come margin ahead consensu
compound-annual-growth-rate time-frame larg line
buysid expect still updat lrp long-rang plan
also seem repres base-cas scenario leav
clear path sustain consist out-performance -- particularli
sale crux op thesi --
contribut new product risk-adjust shave
coupl hundr million total sale bring
estim mani shot goal inclin think
well-posit exceed estim possibl
impact new busi model fulli reflect
first time ever talk becom data-centr
build digit ecosystem hospit effect
like much long-term natur short-term
least believ focu data service/support
deepen relationship hospit custom
increment contribut base manag
commentari analyst meet clear us compani
activ pursu like transform natur
expect ramp activ next month
manag signal discuss around potenti adjac
within busi area highlight could lead
includ biosimilar chronic kidney diseas manag
also believ advanc surgeri busi could benefit inorgan
reiter op pt next month believ share
trade rang dcf valuat deriv
base case upsid scenario supplement
price target arriv via ev/fcf ev/ebitda analys
estim price-to-earnings perspect valuat appli
multipl ep estim assum multipl
expans current level pe ep
support consist beat rais quarter estim
continu move higher
medic suppli devic
pt deriv rang
dcf valuat deriv
base case upsid scenario
supplement ev/fcf ev/
price-to-earnings lt ep growth
compani inform leerink partner llc research
revenu mm ep includ stock compens expens
pleas refer page analyst certif import disclosur price chart disclosur specif
cover compani statement valuat risk avail
rate share outperform price target nine consecut
beat rais ep quarter sinc spin oper margin alreadi track ahead
manag current long-rang plan increasingli strong free cash flow gener
believ post-spin new turnaround stori still room signific upsid
believ increment margin upsid potenti alreadi price believ magnitud
sale growth reacceler potenti free cash flow gener still underappreci
level increasingli becom strong free cash flow gener stori free cash
flow target vs potenti upsid free cash flow
view increas financi flexibl invest busi drive even
faster sale growth acceler invest inorgan outsid opportun
supplement top- bottom-lin growth
given compani solid execut to-dat steadi stream upcom new product launch
addit clari fill gener inject busi increasingli confid
continu drive upsid recent updat long-term growth margin target
believ margin expans stori alreadi least partli price stock
manag current guid oper margin
see room upsid margin ramp believ major upsid
alreadi price share level
sale perspect also see potenti upsid current top-lin growth target
compound-annual-growth-rate time-frame driven new product launch geograph
expans someth feel underappreci street pipelin biggest
driver sale growth acceler next five year expect launch
new product new product expect make total sale
ramp expect signific growth pd periton dialysi gener inject
biosurgeri core growth contributor drive top line grow solid mid-
singl digit higher
overal find bax margin expans stori compel believ investor
underappreci bax sale growth reacceler stori also compani cash-
gener capabl believ ebitda repres relev
measur valu compani vs price earn combin
discount cash flow analysi ev/ebitda ev/fcf arriv month price
yesterday attend bax biannual investor meet nyc bax updat long-
rang plan target sale growth compound-annual-growth-rate time-frame
top-lin growth acceler compound-annual-growth-rate
compound-annual-growth-rate time-frame adjust oper margin expans
guid ramp
top expect continu gener strong free cash flow next
year target expect
innov boost long-term outlook sale growth pois continu acceler
new product launch
us laid clear plan achiev exceed compani
sale growth compound-annual-growth-rate target believ come slightli street
expect sale growth time-frame
figur overview baxter long-term guidanc
compani report factset consensu visibl alpha consensu leerink partner estim
highlight sale contribut new product launch --
discuss detail manag note long-term guidanc
factor risk-adjust reflect execut risk
associ new product launch product launch success
could drive increment bp sale growth bring top-lin growth
compound-annual-growth-rate time-frame
actualnew gbusreclassifi guidanceleerinkconsensusguidanceleerinkconsensusleerinkconsensusguidancemarket growthren growth ex oper tax revenu growth rate constant currenc basi unless otherwis state updat earn call consensu growth compound-annual-growth-rate report outlookcurr long-term
figur overview baxter long-term guidanc -- upsid
compani report factset consensu visibl alpha consensu leerink partner estim
segment highlight product launch
renal renal repres market grow
target above-market sale growth compound-annual-growth-rate time-frame
end-stag renal diseas esrd patient grow steadi assum
price pressur forese futur long-term guidanc came line current
base-cas long-term growth expect street estim busi
expect new product launch contribut sale key launch
kaguya japan launch design address uniqu need
japan market drive penetr pd japan today least
hdx expand hemodialysi therapi enabl theranova new therapi
new dialyz perform closest natur kidney remov larg urem
toxin improv outcom expect complet trial end
launch product
point-of-car poc gener launch significantli
improv qualiti life patient also enabl person
care deliv prescript cycl
compani report factset consensu visibl alpha consensu leerink partner estim
actual baxter baxter baxter growth rate growth rate growth rate sale contribut growth compound-annual-growth-rate bp base case leerink estim base case new productsa actual growth rate growth rate growth rate total sale contribut growth compound-annual-growth-rate bp base case leerink estim base case new product baxter inc
acut therapi address market opportun acut therapi expect grow
impli market growth compound-annual-growth-rate
current hold posit crrp continu renal replac therapi ost
organ support therapi expect achiev above-market growth
time-frame compani drive crrp penetr prismax launch
potenti dedic reimburs code well doubl ost revenu
expect gener sale new product launch
prismax ramp sale
digit connect drive util clinic insight analyt
geograph expans bring sale
compani report factset consensu visibl alpha consensu leerink partner estim
medic deliveri address market opportun medic deliveri expect
grow impli market growth compound-annual-growth-rate
time-frame current hold posit iv therapi infus system
expect drive above-market growth compound-annual-growth-rate time-frame
given continu suppli constraint iv therapi focu improv
manufactur capabl bring million unit iv solut year
upcom spectrum iq launch expect enhanc presenc infus pump
market drive market growth beyond iv therapi infus system plan
drive addit growth entranc new market special monitor pain
expect new product launch contribut sale
upcom spectrum iq infus launch canada
could acceler market share gain
new platform expect includ lvp larg volum infus
pump syring pump common drug librari enterpris gateway allow
integr devic patient monitor
actual therapi therapi therapi growth rate growth rate growth rate total sale contribut growth compound-annual-growth-rate bp base case leerink estim base case new product baxter inc
compani report factset consensu visibl alpha consensu leerink partner estim
pharmaceut molecul expans next five year effect doubl
address market guid pharmaceut sale
growth compound-annual-growth-rate rang time-frame larg driven new
product launch new molecul key therapeut area anesthesia anti-infect
cardiovascular oncolog specialti care translat new product
new registr could potenti bring sale
compani report factset consensu visibl alpha consensu leerink partner estim
nutrit nutrit target sale compound-annual-growth-rate vs market compound-annual-growth-rate
beyond current address market also plan address three adjac
market repres market opportun compani drive standard
ready-to-us nutrit product first-lin therapi pre-term infant drive awar
benefit olimel oncolog patient address elderli patient poor venou
access subcutan administr
expect new product launch contribut sale
oliclinomel china launch
olimel highest protein lowest glucos content three-chamb bag
market expect launch emea
finomel -- uniqu fish-blend three-chamb bag expect launch emea
clinimix hp protein two-chamb bag market
expect launch
actual deliveri deliveri deliveri growth rate growth rate growth rate total sale contribut growth compound-annual-growth-rate bp base case leerink estim base case new productsa actual growth rate growth rate growth rate total sale contribut growth compound-annual-growth-rate bp base case leerink estim base case new product baxter inc
compani report factset consensu visibl alpha consensu leerink partner estim
advanc surgeri renal repres market grow
target above-market sale growth compound-annual-growth-rate
time-frame notabl current hold posit microsurgeri -- current
account sale advanc surgeri segment expect doubl
sale
highlight number product launch throughout portfolio expect
contribut sale includ tisseel prima syring neurotub
coupler remot monitor flosealfast prep arteri
coupl
compani report factset consensu visibl alpha consensu leerink partner estim
near-term margin expans driven continu control innov drive
key piec post-spin stori meaning margin expans opportun
manag guid adjust oper margin
low-hang fruit seemingli pick manag expect margin
improv portfolio transform innov vs cost reduct manag
expect major new product launch margin accret given innov new
product gener higher gross margin
actual growth rate growth rate growth rate total sale contribut growth compound-annual-growth-rate bp base case leerink estim base case new productsa actual surgeri surgeri surgeri growth rate growth rate growth rate total sale contribut growth compound-annual-growth-rate bp base case leerink estim base case new product baxter inc
next month believ share trade rang
dcf valuat deriv base case upsid scenario supplement
ev/fcf ev/ebitda analys ev/ebitda perspect valuat right line
group includ bcr ew
estim
failur execut margin expans initi new product launch delay possibl
acquisit either dilut perceiv further baxter growth goal could
pressur stock
dollar million except asp
good sold
research develop expens
pre-tax incom continu oper
sg sale
 sale
oper expens sale
compani report leerink partner estim
dollar million except asp
total baxter
total baxter
total baxter
total baxter
total baxter
total baxter
total baxter
compani report leerink partner estim
point-of-car solut pd
innov home periton dialysi pd solut system
improv patient access home dialysi new system
design produc steril pd solut use small water filtrat
devic would place patient home integr
sharesourc telehealth platform
theranova technolog design close mimic natur
kidney clearanc certain molecul dialysi get
better level clearanc certain molecul
hdx therapi enabl
hdx therapi extend rang molecul filter
blood dialysi result filtrat profil
close mimic natur kidney addit clearanc profil
hdx enabl theranova simpl perform
convent hemodialysi hd design work
hd machin allow clinic offer hdx therapi use exist
resourc elimin need special equip ad
clinic workflow requir hdf addit hdf
perform effect patient hdx therapi enabl
theranova crucial step bring benefit theranova
patient market
file registr
end
final regulatori pathway fda on-
demand periton dialysi pd system drug-devic combo
expect start clinic trial
oct note market share leader
pd global even introduct poc pd
like grow market rate
januari expect launch
octob begun enrol patient us
first set use continu renal replac therapi
crrt sepsi manag protocol label expans
oxiri blood purif set add baxter multi-organ
therapi offer util prismaflex system
latest technolog acut care therapi
oxiri label expans take effect
countri europ well geographi
east africa began launch label expans
select market outsid
roll-out on-go
februari began limit launch
anticip full european launch later year
expect new product pipelin acceler growth
contribut busi
compani report leerink partner estim
